Felicity Thomas

Cheshire

European Editor at Pharmaceutical Technology

Host at Drug Solutions

Editor, journalist, dabbler in IT sales support and baking, netball player and rugby union enthusiast. Mainly a mum.

Featured in: Favicon

pharmtech.com Favicon

wiley.com

popsugar.com.au Favicon

biopharminternational.com Favicon

epmmagazine.com Favicon

newsbreak.com Favicon

paconsulting.com Favicon

tandfonline.com Favicon

onlinelibrary.wiley.com

Articles

Industry Outlook 2025: European Geopolitical Impact on Pharma

2 weeks ago | biopharminternational.com | Felicity Thomas |Susan Haigney

Political shifts in the United Kingdom and Europe may have a negative impact on research efforts for gene therapies performed by universities and other research organizations, says Alexander Seyf, CEO and co-founder of Autolomous. However, the impact on the bio/pharmaceutical industry is more likely to be minimal.
Ask the Expert: EU Data Protection

3 weeks ago | biopharminternational.com | Felicity Thomas |Susan Haigney

The European Medicines Agency (EMA) announced in December 2024 that the agency and the Heads of Medicines Agencies (HMA) have revised their guidance on identification of commercially confidential information (CCI) and personal data used in marketing authorization applications. The revision was done as part of the agency’s commitment to transparency in the disclosure of information in response to access-to-document requests and the publication of data for authorized medicines (1).
Industry Outlook 2025: Talent Up for Grabs

1 month ago | biopharminternational.com | Felicity Thomas |Susan Haigney

The post-COVID-19 era has seen the consequences of ambitious programs launched during the pandemic, according to Erik Wiklund, CEO of Circio, such as a lack of capital for small biotech and employee layoffs, and Wiklund sees this impacting the industry during 2025. “Many companies launch great ambitions, large valuations.
Industry Outlook 2025: Cell Therapy Advancement

1 month ago | biopharminternational.com | Felicity Thomas |Susan Haigney

Edwin Stone, CEO of Cellular Origins, sees two themes having the biggest impact to the bio/pharma industry: the expansion of glucagon-like peptide-1 (GLP-1) and the growth of cell therapies from fourth- and third-line treatments to second-line treatments. “It really opens up that question of, when do we start to see first line treatments? And of course, part of that comes down to not just the safety and efficacy profiles, but the cost of goods, which still no one has a good answer to,” Stone says.
Ask the Expert: Product Inspection, Part Two; Automated Product Inspection and Cold Chain Considerations

1 month ago | biopharminternational.com | Felicity Thomas |Susan Haigney

In this episode of Ask the Expert, Dirk Margosch, Vice President Visual Inspection, Assembly & Secondary Packaging at Vetter Pharma-Fertigung GmbH & Co KG, addresses the benefits of automating visual inspection, which include increased efficiency and accuracy, and what goes into the cost versus benefit of automating inspection of small batches. “[T] he decision to continue manual inspection for small batch sizes involves several considerations,” says Margosch.
DCAT Week 2025: Recognizing the Value of CDMOs

1 month ago | biopharminternational.com | Felicity Thomas

Therapeutic modalities are diversifying across the bio/pharma industry, explains Simon Wright, vice president of Business Development for Almac Pharma Services. “Whilst there remains a strong demand for traditional small molecules, we see a higher percentage growth in areas such as biologics, vaccines, cell and gene therapies, and I guess, most recently, peptides,” he says.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma

2 months ago | biopharminternational.com | Felicity Thomas

While the pharmaceutical industry has made strides towards diversity, equity, and inclusion, there is still room for improvement, asserts Sheryl Johnson, pharma application development manager at Orbia Fluor & Energy Materials. Many companies, such as Orbia, are taking proactive approaches to help improve gender diverse representations within their workforces. Ongoing commitment from all areas across the industry is required to achieve full diversity, she explains.
Industry Outlook 2025: Personalizing Precision Medicine and Adopting AI

2 months ago | biopharminternational.com | Felicity Thomas

“I do think there's a number of areas that are going to be trends for 2025 and somewhat continuation from this year,” says Preeya Beczek, managing director and co-founder of Beczek.COM Ltd, a specialist in regulatory affairs and compliance.
Industry Outlook 2025: Regulating Technology for the Future

2 months ago | biopharminternational.com | Felicity Thomas

For the bio/pharma industry, 2024 was an interesting year, remarks Kate Coleman, vice president regulatory affairs, quality, and compliance at Arriello, as pharma companies started to take stock of everything and identify the potential areas for value creation in the future. “There's mergers and acquisitions going on, you know, smaller companies looking for acquisition by the larger companies, larger companies trying to acquire pipelines of new drugs,” she says.
Ask the Expert: Complying with 21 CFR 211.110

2 months ago | biopharminternational.com | Felicity Thomas |Susan Haigney

In January 2025, FDA published a draft guidance document that provides considerations for complying with 21 Code of Federal Regulations (CFR) 211.110 (1). This specific section of the CFR focuses on production and process controls for sampling and testing of in-process materials and drug products.